About Clozaril | Videos | CSAN Pronto

Now
available
in Canada!

Introducing CSAN® Pronto™, the newest innovation of
the CSAN® program

CSAN® Pronto™ is a new point-of-care blood monitoring system to help simplify routine bloodwork for your patients on CLOZARIL®
CSAN® Pronto™ is equipped with technology that:

Provides laboratory-accurate WBC counts and NEUT% in real time

Requires only 1 drop of capillary blood (about 3.5 μl) to run the test1

Offers one-step processing, while maintaining CSAN®’s privacy standards1,2

Is designed to address a barrier of CLOZARIL® use by offering the convenience of onsite testing

For Canadian Residents Only | Français

Dear Healthcare Professional,

CSAN® (CLOZARIL® Support and Assistance Network) is a comprehensive support and blood monitoring program that has assured the safe use of CLOZARIL® for Canadians since 1991.

The CSAN® program is offering a new way to help simplify the routine bloodwork of patients on CLOZARIL®.²

We are proud to announce the launch of CSAN® Pronto™ in Canada!

CSAN® Pronto™ is a new point-of-care device indicated for quantitative determination of WBC and NEUT% in capillary blood or K2EDTA venous whole blood.  CSAN® Pronto™ is indicated for in vitro diagnostic use only in clinical laboratory and point-of-care settings by trained healthcare professionals in adult patients. Patients’ results can be provided to your healthcare team in real time and are simultaneously auto- uploaded into your patients’ CSAN® profile using the CSAN Patient Care Portal®.1,2

To learn more, watch the video about this new addition to the CSAN® program, or contact the CSAN® team at 1-800-267-2726

CLOZARIL® (clozapine) is indicated in the management of symptoms of treatment- resistant schizophrenia.3

Please consult the CLOZARIL® Product Monograph for important information on contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use.

The Product Monograph is also available by calling 1-800-267-2726.

For more information on the CSAN® Pronto™ device, consult the Instruction for Use (or User Manual) prior to operating the device. The manual is also available by calling 1-800-267-2726.
References: 1. HLS Therapeutics Inc. CSAN® Pronto™ Device Monograph. 2019. 2. HLS Therapeutics Inc. CLOZARIL® treatment compendium for healthcare professionals. 2018. 3. CLOZARIL® Product Monograph. HLS Therapeutics Inc. September 9, 2019.

Personal Protective Equipment should be worn when processing samples, quality control testing, and during maintenance procedures. During use, CSAN® Pronto™ should be placed on a stable surface, free from movements and any potential vibrations. Operators are not to move the device from one location to another while in operation. CSAN® Pronto™ is only to be used with CSAN® Pronto™ Test Strips. CSAN® Pronto™ Test Strips are single use only.1

NEUT%=neutrophil percentages; WBC=white blood cells.

HLS Therapeutics Inc.
10 Carlson Court,
Suite 701
Etobicoke, Ontario M9W 6L2

  • a1 1-800-267-2726
  • phone4ldpi 1-800-465-1312

Use of this Website is governed by our Terms of Use and Privacy Policy.
MLR20191011

CLOZARIL®, CSAN®, and CSAN Patient Care Portal® + Design are all registered trademarks of Novartis AG.
Pronto is a registered trademark of HLS Therapeutics Inc. All rights reserved.
© Copyright 2016, 2018, 2019, 2023 HLS Therapeutics Inc.